The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp828
STEM-CELL BASED THERAPY FOR NECROTIZING ENTEROCOLITIS
Date
May 8, 2023
Explore related products in the following collection:
Infectious diarrhea is a leading cause of morbidity and of mortality globally. Enteric pathogens that are the cause of most severe acute diarrhea — as assessed by mortality — include Vibrio cholerae, Shigella spp., Salmonella spp., enteropathogenic E. coli(EPEC), and EAEC. The burden of disease affects individuals of all ages but particularly young children, especially those living in poor regions where the disease is endemic. Infectious diarrhea is not only a health concern for international travelers to these areas. While the majority of infections occur in developing countries where contaminated food and drinking water are common, even developed nations cannot escape outbreaks. This session will present and discuss the most recent advances in enteric infection research that will span epidemiology, genetics and gene regulation, vaccine development, host immune response, and cell biology of infection. The broad spectrum of subjects covered at this session, will facilitate interdisciplinary interactions, and ultimately accelerate clinical and basic research aimed at controlling and treating enteric infections.
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…